BioNexus Gene Lab Corp. held its 2024 Annual Meeting where five director nominees were re-elected, but proposals for a stock incentive plan, reverse stock split, and adjournment were not approved; the company also reported potential illegal proxy solicitation affecting voting outcomes and plans to investigate and take legal action.